Zydus Cadila Healthcare Limited - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 73 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Zydus Cadila Healthcare Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Zydus Cadila Healthcare Limited - Product Pipeline Review - 2014', provides an overview of the Zydus Cadila Healthcare Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zydus Cadila Healthcare Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Zydus Cadila Healthcare Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Zydus Cadila Healthcare Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Zydus Cadila Healthcare Limited's pipeline products

Reasons to buy

- Evaluate Zydus Cadila Healthcare Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Zydus Cadila Healthcare Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Zydus Cadila Healthcare Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Zydus Cadila Healthcare Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zydus Cadila Healthcare Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Zydus Cadila Healthcare Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Zydus Cadila Healthcare Limited Snapshot 8
Zydus Cadila Healthcare Limited Overview 8
Key Information 8
Key Facts 8
Zydus Cadila Healthcare Limited - Research and Development Overview 9
Key Therapeutic Areas 9
Zydus Cadila Healthcare Limited - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Zydus Cadila Healthcare Limited - Pipeline Products Glance 17
Zydus Cadila Healthcare Limited - Late Stage Pipeline Products 17
Phase III Products/Combination Treatment Modalities 17
Zydus Cadila Healthcare Limited - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Zydus Cadila Healthcare Limited - Early Stage Pipeline Products 21
IND/CTA Filed Products/Combination Treatment Modalities 21
Preclinical Products/Combination Treatment Modalities 22
Discovery Products/Combination Treatment Modalities 23
Zydus Cadila Healthcare Limited - Unknown Stage Pipeline Products 24
Unknown Products/Combination Treatment Modalities 24
Zydus Cadila Healthcare Limited - Drug Profiles 25
interferon beta-1b 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
saroglitazar 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Vaccine for Live Measles, Mumps and Rubella 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ZYH-7 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ZYOG-1 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PEG-EPO 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Rabimabs Vaccine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Haemophilus Influenzae Type B Conjugated Vaccine 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Live Attenuated Vaccine for Mumps 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Live Attenuated Vaccine for Rubella 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
rituximab biosimilar 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Tetanus Vaccine 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Toxoid Vaccine for Diptheria and Tetanus 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Vaccine for Diptheria, Tetanus and Pertussis 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ZYD-1 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ZYDPLA-1 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ZYG-19 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ZYGK-1 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ZYPH-0907 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ZYT-1 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
MAb-3 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
MAb-4 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Biosimilar 4 for Acute Myocardial Infarction and Infertility 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Drug for Atherosclerotic Plaque 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ZYGL-241 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Biosimilar 1 for Nephrology 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Biosimilar 2 for Diabetes and Rheumatoid Arthritis 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Biosimilar 5 for Infertility 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Biosimilar 6 for Infertility 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Biosimilar 7 for Infertility and Oncology 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MAB-6 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MAb-1 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MAb-2 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Zydus Cadila Healthcare Limited - Pipeline Analysis 60
Zydus Cadila Healthcare Limited - Pipeline Products by Target 60
Zydus Cadila Healthcare Limited - Pipeline Products by Route of Administration 62
Zydus Cadila Healthcare Limited - Pipeline Products by Molecule Type 63
Zydus Cadila Healthcare Limited - Pipeline Products by Mechanism of Action 64
Zydus Cadila Healthcare Limited - Recent Pipeline Updates 66
Zydus Cadila Healthcare Limited - Dormant Projects 67
Zydus Cadila Healthcare Limited - Company Statement 68
Zydus Cadila Healthcare Limited - Locations And Subsidiaries 69
Head Office 69
Other Locations & Subsidiaries 69
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Zydus Cadila Healthcare Limited, Key Information 8
Zydus Cadila Healthcare Limited, Key Facts 8
Zydus Cadila Healthcare Limited - Pipeline by Indication, 2014 11
Zydus Cadila Healthcare Limited - Pipeline by Stage of Development, 2014 13
Zydus Cadila Healthcare Limited - Monotherapy Products in Pipeline, 2014 14
Zydus Cadila Healthcare Limited - Partnered Products in Pipeline, 2014 15
Zydus Cadila Healthcare Limited - Partnered Products/ Combination Treatment Modalities, 2014 16
Zydus Cadila Healthcare Limited - Phase III, 2014 17
Zydus Cadila Healthcare Limited - Phase II, 2014 18
Zydus Cadila Healthcare Limited - Phase I, 2014 19
Zydus Cadila Healthcare Limited - IND/CTA Filed, 2014 21
Zydus Cadila Healthcare Limited - Preclinical, 2014 22
Zydus Cadila Healthcare Limited - Discovery, 2014 23
Zydus Cadila Healthcare Limited - Unknown, 2014 24
Zydus Cadila Healthcare Limited - Pipeline by Target, 2014 61
Zydus Cadila Healthcare Limited - Pipeline by Route of Administration, 2014 62
Zydus Cadila Healthcare Limited - Pipeline by Molecule Type, 2014 63
Zydus Cadila Healthcare Limited - Pipeline Products by Mechanism of Action, 2014 65
Zydus Cadila Healthcare Limited - Recent Pipeline Updates, 2014 66
Zydus Cadila Healthcare Limited - Dormant Developmental Projects,2014 67
Zydus Cadila Healthcare Limited, Subsidiaries 69